Catalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical Officer

Core Insights - Catalyst Pharmaceuticals announced the appointment of Dr. William T. Andrews as Chief Medical Officer, succeeding Dr. Gary Ingenito, who is retiring after a successful career [1][4] - Dr. Andrews brings 24 years of global biopharmaceutical experience, particularly in rare diseases, and has held leadership roles in various biopharmaceutical organizations [2][3] - Catalyst is recognized for its strong financial performance and commitment to improving the lives of patients with rare diseases, focusing on innovative therapies and expanding its global presence [5] Company Overview - Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing therapies for rare diseases, with a strong emphasis on patient care and accessibility [5] - The company has been recognized on the Forbes 2025 list as one of America's Most Successful Mid-Cap Companies and on the 2024 Deloitte Technology Fast 500™ list as one of North America's Fastest-Growing Companies [5]